CJ Bioscience: debt-to-equity, ROE and more
KOSDAQ, Legal name CJ Bioscience
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 34.9%
- Equity ratio
- 74.2%
- ROE
- -44.8%
- Op. margin
- -671.2%
- Rev. growth
- 6.5%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 32.4% | 75.5% | -21.9% | -231.7% | n/a |
| FY2022 consolidated | 84.0% | 54.3% | -70.3% | -815.6% | -6.6% |
| FY2023 consolidated | 27.5% | 78.5% | -32.0% | -575.0% | 36.8% |
| FY2024 consolidated | 28.1% | 78.1% | -42.2% | -987.8% | -37.8% |
| FY2025 consolidated | 34.9% | 74.2% | -44.8% | -671.2% | 6.5% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩4.4B | ₩4.1B | ₩5.6B | ₩3.5B | ₩3.7B |
| Operating profit | -₩10.1B | -₩33.2B | -₩32.1B | -₩34.2B | -₩24.8B |
| Pre-tax income | -₩19.3B | -₩34.9B | -₩22.9B | -₩32.8B | -₩24.0B |
| Net income | -₩19.3B | -₩34.9B | -₩22.9B | -₩32.8B | -₩24.0B |
| Total assets | ₩116.4B | ₩91.4B | ₩91.1B | ₩99.6B | ₩72.3B |
| Total liabilities | ₩28.5B | ₩41.7B | ₩19.6B | ₩21.9B | ₩18.7B |
| Total equity | ₩87.9B | ₩49.7B | ₩71.5B | ₩77.8B | ₩53.6B |
| Paid-in capital | ₩2.9B | ₩2.9B | ₩4.6B | ₩6.5B | ₩6.5B |
| Debt/equity (source value) | 32.4% | 84.0% | 27.5% | 28.1% | 34.9% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2009-11-18
- Listed
- 19/12/26
- Employees
- 102
- Auditor
- 한영회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101114222503
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for CJ 바이오사이언스Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.